BioVie Inc.
BIVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.06 | 0.02 | 0.03 |
| FCF Yield | -30.52% | -4.10% | -6.91% | -27.31% |
| EV / EBITDA | 2.91 | -34.86 | 1.59 | -1.02 |
| Quality | ||||
| ROIC | -20.93% | -18.92% | -13.47% | -30.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 1.61 | 0.45 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 46.07% | -347.34% | 85.40% | -139.83% |
| Safety | ||||
| Net Debt / EBITDA | 4.86 | 5.02 | 7.77 | 3.32 |
| Interest Coverage | -2,656.91 | -732.91 | -597.88 | -109.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,453.35 | 0.00 | 0.00 |